News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's National Institute for Clinical Excellence (NICE) Clears AstraZeneca PLC (AZN) Brilinta Bloodthinner


9/16/2011 7:19:19 AM

AstraZeneca PLC's (AZN) key new heart drug Brilinta has secured final backing from the U.K.'s health-care cost-effectiveness regulator for use on the state-funded National Health Service in England and Wales. The National Institute for Health and Clinical Excellence, or NICE, said the medicine, also known as ticagrelor, is cost-effective and therefore recommends its use in combination with aspirin as a treatment option in adults with acute coronary syndrome. The final decision confirms draft guidance issued by NICE in May.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES